Subgroup analysis in randomised controlled trials: importance, indications, and interpretation

[1]  W. Kalow,et al.  SOME STATISTICAL DATA ON ATYPICAL CHOLINESTERASE OF HUMAN SERUM , 1959, Annals of human genetics.

[2]  V. McKusick,et al.  Genetic Control of Isoniazid Metabolism in Man , 1960, British medical journal.

[3]  J. Tukey.  The Future of Data Analysis , 1962 .

[4]  C. Ruckley,et al.  Prevention of pulmonary embolism. , 1973, British medical journal.

[5]  E. Veys,et al.  Letter: HL-A and infective sacroileitis. , 1974, Lancet.

[6]  H. Keen,et al.  ORAL HYPOGLYCÆMICS IN DIABETES MELLITUS , 1975, The Lancet.

[7]  M. Lipton,et al.  The VA cooperative randomized study of surgery for coronary arterial occlusive disease II. Subgroup with significant left main lesions. , 1976, Circulation.

[8]  R. Hardy,et al.  Controlled Trial of Aspirin in Cerebral Ischemia , 1977, Stroke.

[9]  R. Hardy,et al.  Controlled Trial of Aspirin in Cerebral Ischemia (AITIA Study) , 1979, Thrombosis and Haemostasis.

[10]  F. Pedersen,et al.  EFFECT OF ALPRENOLOL ON MORTALITY AMONG PATIENTS WITH DEFINITE OR SUSPECTED ACUTE MYOCARDIAL INFARCTION Preliminary Results , 1979, The Lancet.

[11]  Furberg Cd,et al.  What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experience. , 1983 .

[12]  R Peto,et al.  Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.

[13]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[14]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.,et al.  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[15]  C. Bulpitt,et al.  Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub-group analysis on entry stratification. , 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[16]  Robert S. Pinals,et al.  A double‐blind, placebo‐controlled trial , 1986 .

[17]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[18]  S. Pocock,et al.  Statistical problems in the reporting of clinical trials. A survey of three medical journals. , 1987, The New England journal of medicine.

[19]  R. Wittes.  Problems in the medical interpretation of overviews. , 1987, Statistics in medicine.

[20]  R A Stallones,et al.  The use and abuse of subgroup analysis in epidemiological research. , 1987, Preventive medicine.

[21]  R. Gelber,et al.  Interpretation of results from subset analyses within overviews of randomized clinical trials. , 1987, Statistics in medicine.

[22]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[23]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[24]  Eli Warnock,et al.  The effect of diltiazem on mortality and reinfarction after myocardial infarction. , 1989, The New England journal of medicine.

[25]  G. Rose.  High-risk and population strategies of prevention: ethical considerations. , 1989, Annals of medicine.

[26]  S. Pocock,et al.  Estimation issues in clinical trials and overviews. , 1990, Statistics in medicine.

[27]  M. Horowitz,et al.  How best to analyse new strategies in bone marrow transplantation. , 1990, Bone marrow transplantation.

[28]  J. Wittes,et al.  Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. , 1991, JAMA.

[29]  K. Anastos,et al.  Hypertension in women: what is really known? The Women's Caucus, Working Group on Women's Health of the Society of General Internal Medicine. , 1991, Annals of internal medicine.

[30]  G H Guyatt,et al.  A Consumer's Guide to Subgroup Analyses , 1992, Annals of Internal Medicine.

[31]  A Morabito,et al.  Prevention of First Bleeding in Cirrhosis , 1992, Annals of Internal Medicine.

[32]  J. Collet,et al.  An Effect Model for the Assessment of Drug Benefit: Example of Antiarrhythmic Drugs in Postmyocardial Infarction Patients , 1993, Journal of cardiovascular pharmacology.

[33]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[34]  Ann Marie Swart,et al.  Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection , 1994, The Lancet.

[35]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.

[36]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[37]  K. Bailey,et al.  Generalizing the results of randomized clinical trials. , 1994, Controlled clinical trials.

[38]  Concorde trial of immediate versus deferred zidovudine. , 1994, Lancet.

[39]  D. Sackett,et al.  Inpatient general medicine is evidence based , 1995, The Lancet.

[40]  J. G. Evans,et al.  Evidence-based and evidence-biased medicine. , 1995, Age and ageing.

[41]  P. Rothwell,et al.  Can overall results of clinical trials be applied to all patients? , 1995, The Lancet.

[42]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[43]  Extrapolation of Trials Data into Practice: Where Is the Limit? , 1995 .

[44]  R. Falk,et al.  Is aspirin safe for patients with heart failure? , 1995, British heart journal.

[45]  D. Sackett.  Applying overviews and meta-analyses at the bedside. , 1995, Journal of clinical epidemiology.

[46]  W. Mali,et al.  Cerebral metabolism of patients with stenosis or occlusion of the internal carotid artery. A 1H-MR spectroscopic imaging study. , 1995, Stroke.

[47]  I. Tannock,et al.  False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons. , 1996, Journal of the National Cancer Institute.

[48]  R. Macnaughton,et al.  Evidence in consultations: interpreted and individualised , 1996, The Lancet.

[49]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[50]  C M O'Connor,et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.

[51]  David J. Weatherall,et al.  Oxford textbook of medicine , 1996 .

[52]  J. Slattery,et al.  A systematic comparison of the risks of stroke and death due to carotid endarterectomy for symptomatic and asymptomatic stenosis. , 1996, Stroke.

[53]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[54]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[55]  J. Berlin,et al.  Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. , 1997, Journal of the American Society of Nephrology : JASN.

[56]  George Davey Smith,et al.  Meta-analysis: Beyond the grand mean? , 1997, BMJ.

[57]  C. Warlow,et al.  Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke , 1997, The Lancet.

[58]  R. Califf,et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .

[59]  A. Feinstein,et al.  Problems in the "evidence" of "evidence-based medicine". , 1997, The American journal of medicine.

[60]  J. Cutler,et al.  Effect of Antihypertensive Drug Treatment on Cardiovascular Outcomes in Women and Men , 1997, Annals of Internal Medicine.

[61]  Christina Wolfson,et al.  Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction , 1997, The Lancet.

[62]  J. Lau,et al.  The impact of high-risk patients on the results of clinical trials. , 1997, Journal of clinical epidemiology.

[63]  J. Berlin,et al.  The Effect of Antilymphocyte Induction Therapy on Renal Allograft Survival , 1998, Annals of Internal Medicine.

[64]  Didier Martin,et al.  Unruptured intracranial aneurysms--risk of rupture and risks of surgical intervention. , 1998, The New England journal of medicine.

[65]  Identification des sujets répondeurs à une thérapeutique : Proposition de modèle et application préliminaire à l'hypertension , 1998 .

[66]  S. Burdett,et al.  Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials , 1998, The Lancet.

[67]  J. Slattery,et al.  Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST) , 1998, The Lancet.

[68]  William J. Powers,et al.  Importance of Hemodynamic Factors in the Prognosis of Symptomatic Carotid Occlusion , 1998 .

[69]  S. Senn.  Applying results of randomised trials to patients , 1998, BMJ.

[70]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[71]  E. Kun,et al.  Treatment of Cancer , 1998 .

[72]  A R Feinstein,et al.  The problem of cogent subgroups: a clinicostatistical tragedy. , 1998, Journal of clinical epidemiology.

[73]  Christopher H Schmid,et al.  Summing up evidence: one answer is not always enough , 1998, The Lancet.

[74]  J. Toole,et al.  Guidelines for carotid endarterectomy: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. , 1998, Circulation.

[75]  Identification and prediction of responders to a therapy: A model and its preliminary application to actual data , 1998 .

[76]  D. Sackett,et al.  Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. , 1998, The New England journal of medicine.

[77]  J. Toole,et al.  Guidelines for carotid endarterectomy: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. , 1998, Stroke.

[78]  T. Fahey.  Applying the results of clinical trials to patients to general practice: perceived problems, strengths, assumptions, and challenges for the future. , 1998, The British journal of general practice : the journal of the Royal College of General Practitioners.

[79]  J Lau,et al.  Uncontrolled pearls, controlled evidence, meta-analysis and the individual patient. , 1998, Journal of clinical epidemiology.

[80]  D. Black.  The Limitations of Evidence , 2015, Journal of the Royal College of Physicians of London.

[81]  D. Sackett,et al.  Finding and applying evidence during clinical rounds: the "evidence cart". , 1998, JAMA.

[82]  W. Hacke,et al.  Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. , 1999, Neurology.

[83]  J. Gladman,et al.  Limitations of clinical diagnosis in acute stroke , 1999, The Lancet.

[84]  R Brian Haynes,et al.  Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial , 1999, The Lancet.

[85]  David Mant,et al.  Can randomised trials inform clinical decisions about individual patients? , 1999, The Lancet.

[86]  C. Warlow,et al.  Prediction of benefit from carotid endar terectomy in individual patients: a risk-modelling study , 1999, The Lancet.

[87]  Karla Kerlikowske,et al.  Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials , 1999, The Lancet.

[88]  J. Swales.  Evidence-based medicine and hypertension. , 1999, Journal of hypertension.

[89]  S. Assmann,et al.  Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.

[90]  A. Keech,et al.  Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project , 2000, Circulation.

[91]  I. Chalmers.  A Patient's Attitude to the Use of Research Evidence for Guiding Individual Choices and Decisions in Healthcare , 2000 .

[92]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[93]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[94]  J L Hutton,et al.  Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies. , 2000, Statistics in medicine.

[95]  A. Kastrati,et al.  Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial , 2001, The Lancet.

[96]  E. Antman,et al.  The TIMI risk score for unstable angina/non–ST-elevation MI: a method for prognostication and therapeutic decision making , 2001 .

[97]  T. Peters,et al.  Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. , 2001, Health technology assessment.

[98]  L. Caplan,et al.  Evidence based medicine: concerns of a clinical neurologist , 2001, Journal of neurology, neurosurgery, and psychiatry.

[99]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[100]  Morris J. Brown,et al.  Matching the right drug to the right patient in essential hypertension , 2001, Heart.

[101]  E. Oren,et al.  Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.

[102]  E. Susser,et al.  Reporting on methods of subgroup analysis in clinical trials: a survey of four scientific journals. , 2001, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[103]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[104]  P. Ghahramani,et al.  Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials , 2001, Heart.

[105]  R. Collins,et al.  Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials , 2001, The Lancet.

[106]  Thompson G. Robinson,et al.  National Clinical Guidelines for Stroke. , 2001 .

[107]  D. Johnston.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.

[108]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[109]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[110]  S. Yusuf,et al.  Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups , 2002, Circulation.

[111]  P. Quirke,et al.  DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study , 2002, The Lancet.

[112]  E. Schiffrin,et al.  The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. , 2002, The Canadian journal of cardiology.

[113]  J. Hampton.  Size isn't everything , 2002, Statistics in medicine.

[114]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[115]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[116]  E. Bleecker,et al.  Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. , 2002, The New England journal of medicine.

[117]  Yi Tsong,et al.  ISSUES RELATED TO SUBGROUP ANALYSIS IN CLINICAL TRIALS , 2002, Journal of biopharmaceutical statistics.

[118]  A. Telenti,et al.  Individualising HIV treatment—pharmacogenetics and immunogenetics , 2002, The Lancet.

[119]  R. Weinshilboum.  Inheritance and drug response. , 2003, The New England journal of medicine.

[120]  A. Blamire,et al.  Interictal cellular energy reserves in migraineurs with prolonged aura or coma and migrainous stroke: A brain P-31-MR-spectroscopy study , 2003 .

[121]  P. Rothwell,et al.  Relationship Between Blood Pressure and Stroke Risk in Patients With Symptomatic Carotid Occlusive Disease , 2003, Stroke.

[122]  P. Rothwell,et al.  Systematic review of the risks of carotid endarterectomy in relation to the clinical indication for and timing of surgery. , 2003, Stroke.

[123]  G. Wagner,et al.  Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. , 2003, Journal of the American College of Cardiology.

[124]  M. Eliasziw,et al.  Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis , 2003, The Lancet.

[125]  J. Rouleau,et al.  Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. , 2003, American heart journal.

[126]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[127]  P. Rothwell,et al.  Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services , 2004, BMJ : British Medical Journal.

[128]  P. Rothwell,et al.  Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies , 2004, Neurology.

[129]  M. Eliasziw,et al.  Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery , 2004, The Lancet.

[130]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.